Baidu
map

Int Forum Allergy Rhinol:儿童中过敏性鼻炎和夜尿症相关风险研究

2018-10-17 AlexYang MedSci原创

尽管有争论,过敏和夜尿症(NE)之间的相关性在近一个世纪里均有报道。过敏性鼻炎(AR)相关的睡眠障碍呼吸经常导致睡眠的微觉醒,从而减少了睡眠的质量,改变了睡眠模式和行为。NE是儿童中一种常见的睡眠障碍。因此,有研究人员调查了AR儿童的NE发生和风险情况。研究是一个基于群体的研究,包括了327928名患有AR的儿童和327601名不患有AR的对照儿童。时间为2012年,地点为中国台湾到2012年。研

尽管有争论,过敏和夜尿症(NE)之间的相关性在近一个世纪里均有报道。过敏性鼻炎(AR)相关的睡眠障碍呼吸经常导致睡眠的微觉醒,从而减少了睡眠的质量,改变了睡眠模式和行为。NE是儿童中一种常见的睡眠障碍。因此,有研究人员调查了AR儿童的NE发生和风险情况。

研究是一个基于群体的研究,包括了327928名患有AR的儿童和327601名不患有AR的对照儿童。时间为2012年,地点为中国台湾到2012年。研究人员对NE在2个群体中的发生率,以及过敏和非过敏风险比(HRs)进行了测量。研究发现,研究期间在AR群体中,NE调整后的HR为非AR组的1.7倍。风险在男孩、小于6岁、具有哮喘和过敏性皮肤炎并发症和注意力缺陷障碍(ADHD)和那些超过5年过敏性鼻炎治疗史的儿童中风险更大。另外,NE在AR群体中的风险随着跟踪调查时间减少,并且在AR诊断的第一年风险最高。

最后,研究人员指出,患有AR的儿童NE的发生和风险更高,并且NE在男孩、小年纪和更多的AR症状治疗儿童中风险更大。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047031, encodeId=0ab3204e03160, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 11 07:22:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055643, encodeId=6d7f205564343, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 24 20:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350062, encodeId=1090350062a3, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:13 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329163, encodeId=4a4d132916346, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 19 04:22:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349651, encodeId=9d9234965103, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 17 13:54:10 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047031, encodeId=0ab3204e03160, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 11 07:22:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055643, encodeId=6d7f205564343, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 24 20:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350062, encodeId=1090350062a3, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:13 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329163, encodeId=4a4d132916346, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 19 04:22:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349651, encodeId=9d9234965103, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 17 13:54:10 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047031, encodeId=0ab3204e03160, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 11 07:22:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055643, encodeId=6d7f205564343, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 24 20:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350062, encodeId=1090350062a3, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:13 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329163, encodeId=4a4d132916346, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 19 04:22:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349651, encodeId=9d9234965103, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 17 13:54:10 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-21 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2047031, encodeId=0ab3204e03160, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 11 07:22:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055643, encodeId=6d7f205564343, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 24 20:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350062, encodeId=1090350062a3, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:13 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329163, encodeId=4a4d132916346, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 19 04:22:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349651, encodeId=9d9234965103, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 17 13:54:10 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-19 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047031, encodeId=0ab3204e03160, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Mar 11 07:22:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055643, encodeId=6d7f205564343, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 24 20:22:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350062, encodeId=1090350062a3, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:13 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329163, encodeId=4a4d132916346, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Oct 19 04:22:00 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349651, encodeId=9d9234965103, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 17 13:54:10 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-17 122b87b4m49(暂无昵称)

    学习了,谢谢

    0

相关资讯

Am J Kidney Dis:ESRD患儿死亡风险的性别差异

由此可见,女孩的死亡率远高于接受RRT治疗的男孩。女孩接受移植的比例低于男孩,但接受移植的差异只占性别所致存活差异的一小部分。

Nat Commun:对年轻癌症患者进行全基因组测序势在必行

在最近的一项研究中,圣裘德儿童研究医院的科学家显示,将全基因组测序纳入临床基因组测试,可以在近一半的患者中发现更多的致癌基因突变。此举为临床基因组测试提供了一个新的黄金标准,并强调了将全基因组测序纳入儿科癌症患者临床测试和治疗的迫切需要。

儿童颅内非典型畸胎样/横纹肌样瘤2例

非典型畸胎样/横纹肌样瘤(atypical teratoid/rhabdoid tumor,AT/RT)属于胚胎性肿瘤之一,由Biggs等首次报道,发病率极低,占儿童颅内肿瘤1%~3%,70%~90%以上发病于低龄儿童(<3岁)。AT/RT 恶性度极高,预后极差,中位生存期0.5~1年。2014年收治2例儿童颅内AT/RT,现报道如下。

PLoS One:小学儿童中,过敏相关的障碍(ARDs)研究

过敏性相关的障碍(ARDs)的流行度具有显著的增加,城市化被认为是ARDs发生的一个主要的环境风险因子,但是中低收入国家的相关数据有限。最近,有研究人员评估了ARDs和特应性反应在埃塞俄比亚乡村学生儿童群体中的流行度,并且鉴定了障碍的相关环境和生活方式因素。研究是一个代表性的研究,包括了541名学生儿童。研究参与者的女性占比60.3%,年龄为10-15岁。ARD的流行度为27%,曾经患有湿疹、鼻炎

Aust J Gen Pract:增殖腺扁桃体切除术后,伴随残余打鼾和睡眠症状儿童过敏性鼻炎发生率研究

在儿童中,过敏性鼻炎对睡眠障碍呼吸(SDB)具有贡献性作用。尽管增殖腺扁桃体切除术经常用来治疗SDB,一些患者仍旧会伴随残余的睡眠症状并回诊。最近,有研究人员在经历增殖腺扁桃体切除术的儿童中通过放射变应性吸附法测试(RAST)对过敏性鼻炎的发生率进行评估,这些儿童均具有残余的打鼾或者睡眠障碍现象。研究是一个回顾性的研究,包括了500名增殖腺扁桃体切除术术后的儿童。研究人员评估和记录了残余的打鼾、睡

NEJM:研究揭示预防肥胖的关键时期

一项大型研究发现,大多数肥胖青少年在2~6岁的儿童早期体重增加最明显,之后体重增加速度减慢但仍在继续增加,导致青少年期肥胖程度更高。

Baidu
map
Baidu
map
Baidu
map